Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts
- 1 September 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 79 (17) , 4539-4550
Abstract
Identifying robust biomarkers of drug response constitutes a key challenge in precision medicine. Patient-derived tumor xenografts (PDX) have emerged as reliable preclinical models that more accurately recapitulate tumor response to chemo- and targeted therapies. However, the lack of computational tools makes it difficult to analyze high-throughput molecular and pharmacologic profiles of PDX. We have developed Xenograft Visualization & Analysis (Xeva), an open-source software package for in vivo pharmacogenomic datasets that allows for quantification of variability in gene expression and pathway activity across PDX passages. We found that only a few genes and pathways exhibited passage-specific alterations and were therefore not suitable for biomarker discovery. Using the largest PDX pharmacogenomic dataset to date, we identified 87 pathways that are significantly associated with response to 51 drugs (FDR < 0.05). We found novel biomarkers based on gene expressions, copy number aberrations, and mutations predictive of drug response (concordance index > 0.60; FDR < 0.05). Our study demonstrates that Xeva provides a flexible platform for integrative analysis of preclinical in vivo pharmacogenomics data to identify biomarkers predictive of drug response, representing a major step forward in precision oncology. Significance: A computational platform for PDX data analysis reveals consistent gene and pathway activity across passages and confirms drug response prediction biomarkers in PDX. See related commentary by Meehan, p. 4324Keywords
All Related Versions
Funding Information
- Canadian Cancer SocietyCanadian Cancer Society (Société canadienne du cancer)
- Ontario Institute for Cancer ResearchOntario Institute for Cancer Research (OICR) (SU2C-AACR-DT-18-15)
- Canadian Breast Cancer FoundationCanadian Breast Cancer Foundation (CBCF)
- Terry Fox Research InstituteTerry Fox Research Institute (TFRI)
This publication has 51 references indexed in Scilit:
- Enriching the gene set analysis of genome-wide data by incorporating directionality of gene expression and combining statistical hypotheses and methodsNucleic Acids Research, 2013
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Characterization of a Large Panel of Patient-Derived Tumor Xenografts Representing the Clinical Heterogeneity of Human Colorectal CancerClinical Cancer Research, 2012
- Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal CarcinomasClinical Cancer Research, 2012
- Raise standards for preclinical cancer researchNature, 2012
- Molecular profiling of patient-derived breast cancer xenograftsBreast Cancer Research, 2012
- Differential genome-wide profiling of tandem 3′ UTRs among human breast cancer and normal cells by high-throughput sequencingGenome Research, 2011
- Colorectal Cancer Cell Lines Lack the Molecular Heterogeneity of Clinical Colorectal TumorsClinical Colorectal Cancer, 2010
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- A Serial Analysis of Gene Expression (SAGE) Database Analysis of ChemosensitivityCancer Research, 2004